European Union Authorizes Eylea 8 mg with Prolonged 6-Month Treatment Schedule
European Commission Grants Approval for Eylea™ 8 mg with Extended 6-Month Dosing Interval in Patients with nAMD and DME The European Commission (EC) has officially approved a label extension for…
Biogen Shares Promising Nusinersen Data in Continued Mission to Improve Lives of Those with
Biogen Unveils New Data Underscoring the Long-Term Benefits and Advancements of Nusinersen in Spinal Muscular Atrophy Treatment Biogen, a global leader in neuroscience, has announced compelling new data that reinforces…
Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia
Viatris Reports Positive Top-Line Results from Pivotal Phase 3 VEGA-3 Trial of MR-141 for Presbyopia, Underscoring Its Potential as a Non-Invasive Vision Correction Therapy Viatris, a global healthcare company committed…
Incyte Names Bill Meury as CEO as Hervé Hoppenot Announces Retirement
Incyte Appoints Bill Meury as President and CEO, Succeeding Hervé Hoppenot Amid Strategic Leadership Transition In a pivotal leadership transition that marks a new chapter in its corporate journey, Incyte…
BeOne Medicines Presents Transformative Oncology Portfolio at Research & Development Day
BeOne Medicines Showcases Bold Vision and Expansive Oncology Pipeline at 2025 R&D Day BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its…
WuXi AppTec’s Nantong Facility Honored with 2025 Architizer A+Award for Seamlessly Integrating Technology and Human-Centered Design
WuXi AppTec’s Nantong Facility Wins 2025 Architizer A+Award for Excellence in Human-Centered Industrial Design WuXi AppTec, a globally recognized provider of research, development, and manufacturing services for the pharmaceutical and…
CVS Health Expands Workforce Training with New Chicago Innovation Center
CVS Health Launches Workforce Innovation and Talent Center in Chicago to Strengthen Community Employment and Training Opportunities In a significant step toward fostering economic opportunity and addressing workforce gaps, CVS…
FDA Approves Label Updates for Bristol Myers Squibb Cell Therapies, Removes REMS
FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a…
Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV
Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. CDC panel backs long-acting monoclonal antibody to protect infants during…
Global Energy Access Improves, But More International Financial Support Needed to Close the Gap
Global Energy Access Expands, But Urgent Financing Needed to Bridge Persistent Gaps and Achieve SDG 7 by 2030 A newly released edition of the Tracking SDG 7: The Energy Progress…
BeOne Medicines Gains CHMP Backing for BRUKINSA Tablet Formulation
BeOne Medicines Receives Positive CHMP Opinion for New Film-Coated Tablet Formulation of BRUKINSA® (zanubrutinib), Paving the Way for European Market Approval BeOne Medicines Ltd. a globally operating oncology-focused biopharmaceutical company,…
Biogen Advances Investigational SMA Therapy to Registrational Trials After Positive Phase 1 Data
Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating…